DK0505497T3 - Sårbehandling under anvendelse af biologisk aktive peptider - Google Patents

Sårbehandling under anvendelse af biologisk aktive peptider

Info

Publication number
DK0505497T3
DK0505497T3 DK91902831T DK91902831T DK0505497T3 DK 0505497 T3 DK0505497 T3 DK 0505497T3 DK 91902831 T DK91902831 T DK 91902831T DK 91902831 T DK91902831 T DK 91902831T DK 0505497 T3 DK0505497 T3 DK 0505497T3
Authority
DK
Denmark
Prior art keywords
biologically active
wound treatment
active peptides
wound
host
Prior art date
Application number
DK91902831T
Other languages
Danish (da)
English (en)
Inventor
Barry Berkowitz
Leonard S Jacob
Michael Zasloff
Original Assignee
Magainin Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magainin Pharma filed Critical Magainin Pharma
Application granted granted Critical
Publication of DK0505497T3 publication Critical patent/DK0505497T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
DK91902831T 1989-12-18 1990-12-12 Sårbehandling under anvendelse af biologisk aktive peptider DK0505497T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/451,777 US5045531A (en) 1989-12-18 1989-12-18 Wound treatment employing biologically active ion channel forming peptides and proteins
PCT/US1990/007440 WO1991008758A1 (fr) 1989-12-18 1990-12-12 Traitement des plaies utilisant des peptides biologiquement actifs

Publications (1)

Publication Number Publication Date
DK0505497T3 true DK0505497T3 (da) 1999-11-22

Family

ID=23793638

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91902831T DK0505497T3 (da) 1989-12-18 1990-12-12 Sårbehandling under anvendelse af biologisk aktive peptider

Country Status (10)

Country Link
US (2) US5045531A (fr)
EP (1) EP0505497B1 (fr)
JP (1) JPH05504566A (fr)
AT (1) ATE181835T1 (fr)
CA (1) CA2032059C (fr)
DE (1) DE69033200T2 (fr)
DK (1) DK0505497T3 (fr)
ES (1) ES2136599T3 (fr)
GR (1) GR3031459T3 (fr)
WO (1) WO1991008758A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970006154B1 (ko) * 1987-07-06 1997-04-24 루이지아나 스테이트 유니버시티 아그리컬춰럴 앤드 메카니칼 컬리지 용해성 펩티드에 의한 진핵 병원체와 신생물의 억제 및 섬유아세포와 임파구의 자극
CA1327311C (fr) * 1987-07-06 1994-03-01 Jesse M. Jaynes Polypeptides antimicrobiens therapeutiques, leurs methodes de preparation et leurs usages
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
US5912231A (en) * 1989-07-07 1999-06-15 Scripps Clinic And Research Foundation Substitution analogues of magainin peptides
US5242902A (en) * 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
NZ237202A (en) * 1990-02-23 1994-01-26 Bristol Myers Squibb Co Composition containing beta-lactam antibiotic and cationic oligopeptide
AU648140B2 (en) * 1991-02-01 1994-04-14 Virtual Drug Development, Inc. Reverse antimicrobial peptides and antimicrobial compositions
AU667479B2 (en) * 1991-06-12 1996-03-28 Magainin Pharmaceuticals, Inc. Treating the oral cavity with ion-channel forming peptides
AU673190B2 (en) * 1992-07-13 1996-10-31 Bionebraska, Inc. Method for modification of recombinant polypeptides
US5656456A (en) * 1992-07-13 1997-08-12 Bionebraska, Inc. Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof
US5593866A (en) * 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
WO1994019369A1 (fr) * 1993-02-26 1994-09-01 Magainin Pharmaceuticals, Inc. Traitement de tumeurs cancereuses au moyen d'inhibiteurs de protease et de peptides a activite biologique
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5968904A (en) * 1993-06-04 1999-10-19 Demegen, Inc. Modified arginine containing lytic peptides and method of making the same by glyoxylation
US5561107A (en) * 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
US5856178A (en) * 1993-08-30 1999-01-05 Utah State University DNA cassettes for expression of lytic peptides in mammalian cells and transgenic organisms containing same
WO1995011670A1 (fr) * 1993-10-25 1995-05-04 The Liposome Company, Inc. Defensines liposomiques
AU1086595A (en) 1993-11-08 1995-05-29 Demeter Biotechnologies, Ltd. Methylated lysine-rich lytic peptides and method of making same by reductive alkylation
US6057291A (en) 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
FR2735983B1 (fr) 1995-06-29 1997-12-05 Centre Nat Rech Scient Peptide permettant de modifier l'activite du systeme immunitaire humain ou animal
JP3860838B2 (ja) 1995-08-23 2006-12-20 ユニバーシティー オブ ブリティッシュ コロンビア 抗微生物性陽イオン性ペプチドおよびそのスクリーニング方法
US6077826A (en) * 1996-01-25 2000-06-20 Kansas State University Research Foundation Synthetic macromolecular channel assembly for transport of chloride ions through epithelium useful in treating cystic fibrosis
EP0935965A4 (fr) * 1996-04-23 2002-01-23 Toray Industries Agent anti-pylori
DE10051983A1 (de) * 2000-10-20 2002-06-13 Beate Kehrel Inhibierung der pathogenen Wirkung oxidierter Proteine
WO2005094423A2 (fr) * 2004-02-26 2005-10-13 President And Fellows Of Harvard College Inhibition selective des proteasomes de la tuberculose et d'autres bacteries
WO2009070564A2 (fr) * 2007-11-27 2009-06-04 Macrochem Corporation Compositions et procédés utilisables dans le cadre de la prévention d'infections associées à des implants transcutanés ostéointégrés
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507230A (en) * 1982-05-12 1985-03-26 Research Corporation Peptide synthesis reagents and method of use
US4863899A (en) * 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4810777A (en) * 1987-03-04 1989-03-07 The United States Of America As Represented By The Department Of Health And Human Services Antimicrobial compounds
US5164370A (en) * 1987-12-24 1992-11-17 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
US4962277A (en) * 1988-12-09 1990-10-09 Scripps Clinic And Research Foundation Deletion analogues of magainin peptides
US5073542A (en) * 1989-06-07 1991-12-17 Magainin Sciences Inc. CPF peptide compositions and their use in inhibiting growth of target cells or a virus

Also Published As

Publication number Publication date
ES2136599T3 (es) 1999-12-01
CA2032059C (fr) 2003-02-25
EP0505497A4 (en) 1993-09-08
GR3031459T3 (en) 2000-01-31
US5045531A (en) 1991-09-03
WO1991008758A1 (fr) 1991-06-27
EP0505497A1 (fr) 1992-09-30
DE69033200T2 (de) 2000-02-24
EP0505497B1 (fr) 1999-07-07
DE69033200D1 (de) 1999-08-12
CA2032059A1 (fr) 1991-06-19
USRE35492E (en) 1997-04-08
JPH05504566A (ja) 1993-07-15
ATE181835T1 (de) 1999-07-15

Similar Documents

Publication Publication Date Title
DK0505497T3 (da) Sårbehandling under anvendelse af biologisk aktive peptider
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
ES2196640T3 (es) Dispositivo terapeutico transdermico con capsaicina y analogos de capsaicina.
ATE63813T1 (de) Pharmazeutische zusammensetzungen von dihydrocodeine/ibuprofen und verfahren.
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
EP0802782A4 (fr) Traitement prophylactique et therapeutique de la sensibilisation et de l'irritation cutanee
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
GEP20002146B (en) Therapeutic Peptide Derivatives
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
RU95106651A (ru) Аналоги дзе-тур динорфина и способ лечения толерантных состояний у пациента
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
NO922953L (no) Rekombinant fremstilt blodfaktorer og fremgangsmaate for ekspresjon av blodfaktorene, samt vacciniavirusrekombinanter
ATE210149T1 (de) Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE59005281D1 (de) Pharmazeutische präparate.
DK403384A (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
ATE111483T1 (de) Biologisch wirksame moleküle.
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
ATE107170T1 (de) Zusammensetzung und behandelung mittels biologisch aktiven peptiden und bestimmten anionen.
DE69739482D1 (de) Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
RU94044795A (ru) Способ лечения невралгии тройничного нерва
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio
NO911470L (no) Sammensetning og behandling med biologisk aktive peptiderog visse anioner.